Equities

DVx Inc

3079:TYO

DVx Inc

Actions
Health CareMedical Equipment and Services
  • Price (JPY)993.00
  • Today's Change-3.00 / -0.30%
  • Shares traded4.90k
  • 1 Year change+15.06%
  • Beta0.3203
Data delayed at least 20 minutes, as of Jul 26 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DVx Inc. is a Japan-based company mainly engaged in the sale of medical equipment for circulatory system diseases. The Company operates in two business segments. The Arrhythmia segment mainly sells cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), electrode catheters and ablation catheters. The Ischemia segment is engaged in the import and sale of automated contrast medium injectors under the name ACIST, excimer laser angioplasty systems, as well as sale of coronary artery stent products as agency business. The others business is engaged in the sale of neurosurgical products, general surgery related products, gastrointestinal related products, radiation protection supplies, among others.

  • Revenue in JPY (TTM)45.85bn
  • Net income in JPY172.91m
  • Incorporated1986
  • Employees316.00
  • Location
    DVx Inc5F, Mejiro Nakano Bldg., 2-17-22, TakadaTOSHIMA-KU 171-0033JapanJPN
  • Phone+81 359856123
  • Fax+81 359856106
  • Websitehttps://www.dvx.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kowa Co Ltd6.39bn726.57m5.46bn213.006.701.755.720.8541162.57162.571,414.88623.861.242.825.8729,992,250.0014.386.0623.339.1045.6846.3711.625.391.1013.550.276222.732.167.1962.08---10.57--
KAINOS Laboratories, Inc.5.16bn681.84m5.48bn146.007.400.80249.371.06162.48162.481,229.071,499.230.63772.993.4235,360,720.008.426.9210.559.2651.3851.8413.2110.802.92--0.111119.622.711.6012.2810.57-9.8316.36
Leoclan Co Ltd27.19bn348.28m6.08bn176.0017.491.0613.070.2235176.63176.6313,790.692,908.781.88610.314.25154,469,600.002.503.095.597.1610.9610.091.331.461.83--0.0018.56-10.530.7026-37.92-5.3819.25--
Precision System Science Co., Ltd.4.01bn-1.34bn6.11bn199.00--1.33--1.52-48.33-48.33145.18165.790.46051.565.2220,158,780.00-15.33-1.10-19.53-1.4720.9131.92-33.29-1.481.66-36.870.2387---29.007.71-3,020.99--6.22--
Yamashita Health Care Holdings Inc61.56bn580.00m6.67bn570.0011.460.761511.180.1083227.80227.8024,179.093,428.752.4117.935.58--2.262.236.656.4513.8112.460.9390.84721.02----32.225.770.0071164.8432.063.8410.76
Data Horizon Co Ltd5.16bn-610.45m7.03bn380.00--2.00--1.36-48.20-48.20407.67275.820.616529.051.7513,587,990.00-7.72-4.67-15.36-7.0032.0644.60-12.53-3.610.8997-35.850.5456--47.4911.63-61.85--48.07--
Koken Ltd10.04bn538.47m8.43bn287.0015.150.65948.350.8395108.96108.962,031.292,503.850.47272.222.6434,975,880.002.543.703.174.7545.5046.695.367.191.8819.130.33325.88-0.16054.92-15.8414.33-39.876.96
Create Medic Co Ltd12.69bn83.34m9.12bn962.00102.820.562313.220.71889.189.181,395.571,678.910.66781.734.3913,193,190.000.43853.000.51453.5343.6845.360.65674.602.98--0.050363.222.103.11-68.06-25.530.66271.12
DVx Inc45.85bn172.91m10.74bn316.0059.981.1317.740.234216.6116.614,394.81880.721.9826.604.02145,098,300.000.74743.111.777.5710.3911.600.37711.491.51--0.001447.57-3.442.57-81.53-29.2311.2315.81
OLBA Healthcare Holdings Inc117.02bn1.50bn12.64bn1.32k8.081.116.180.108250.44250.4419,539.551,826.782.6616.204.3288,854,800.003.402.7112.139.7811.5811.061.280.91740.9764152.760.162732.162.330.5165-7.896.06-6.4211.84
JMS Co Ltd65.29bn-36.00m12.66bn5.28k--0.30893.450.194-1.49-1.492,668.181,657.260.82072.784.0712,358,890.00-0.05781.33-0.08651.9721.5924.29-0.07051.570.987-89.330.397943.312.432.38-112.81---2.421.22
EcoNaviSta Inc1.17bn273.12m14.26bn35.0059.534.4948.1712.1637.3837.38175.91495.790.46881.689.5033,514,490.0010.92--12.19--65.00--23.28--11.53--0.00--21.55--38.02------
Kusurinomadoguchi Inc8.72bn870.92m15.13bn505.0016.552.387.931.7383.2483.24841.21580.15------17,270,220.00--------56.56--10.03----898.950.4574--17.53--122.49------
Techno Medica Co Ltd10.28bn1.35bn15.24bn237.009.590.870510.431.48181.53181.531,319.311,998.920.55772.552.6543,391,780.007.316.688.787.8050.1048.8613.1112.313.85--0.0039.339.781.9617.154.190.71687.67
Data as of Jul 26 2024. Currency figures normalised to DVx Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

5.14%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 15 Jun 2023402.00k3.73%
Nomura Asset Management Co., Ltd.as of 31 May 202461.00k0.57%
Nikko Asset Management Co., Ltd.as of 05 Jul 202429.40k0.27%
Daiwa Asset Management Co. Ltd.as of 28 Jun 202427.40k0.25%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jul 202412.60k0.12%
BlackRock Japan Co. Ltd.as of 04 Jul 20246.40k0.06%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 19 Feb 20244.80k0.05%
Nissay Asset Management Corp.as of 21 Feb 20234.70k0.04%
Asset Management One Co., Ltd.as of 04 Jul 20243.80k0.04%
Amundi Asset Management SA (Investment Management)as of 03 Jul 20241.93k0.02%
More ▼
Data from 31 Mar 2024 - 18 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.